In the early years of the United States, several American presidents were in favour of public health inoculation and vaccination strategies.
Academic rigor, journalistic flair
Articles on COVID-19 vaccines
Displaying 461 - 480 of 576 articles
CC BY-NC-ND16.4 MB (download)
It’s unlikely South Africa will have a substantial number of vaccines until the second half of this year. Most of the vaccines produced in Europe or America have been bought by other countries.
Massive vaccine distribution efforts take a lot of coordination. The rollout of the Salk polio vaccine in the US in 1955 holds lessons for those delivering COVID-19 shots today.
Two in five Americans say they don’t want a COVID-19 vaccine, which is a problem. Finding out what Americans do want from a vaccine might help.
The best approach for protecting everyone’s health will require us to provide different vaccines to different people according to need and availability.
Despite the latest tweaks to border testing rules, the risk of imported infection remains very high. NZ’s wider response needs upgrading —including reducing the large numbers of infected returnees.
With reports emerging of vaccine wastage across the world, medical supply chain experts explain why that’s to be expected.
A waiver on some intellectual property rules at the WTO for COVID-19 vaccines would ensure more equitable access, but wouldn’t solve all the problems facing developing countries.
The shipment of goods to suppliers has become technologically sophisticated. Delays in getting out the COVID-19 vaccine to people show that the breakdowns come down to something more basic.
COVID-19 vaccines could substantially reduce hospital admissions, but will be slower at freeing up space in intensive care.
A medical professor explains the reasoning behind the delay in the UK and what impact this might have on the vaccine’s effectiveness.
Australia’s expedited plan to start dishing out COVID jabs in mid-late February will call for NASA-like logistical organisation. And ideally, no more clusters of infections to distract frontline workers.
Our research can help understand the role schools play in transmission.
Researchers say around 70% of the US needs to get the coronavirus vaccine to stop the pandemic. But questions around the vaccines and regional differences add some uncertainty to that estimate.
Even though the idea has been rejected earlier in the COVID-19 pandemic, we need to rethink immunity passports. Here’s why.
Black people are skeptical about the new vaccines for many reasons. If public health leaders told the full story, maybe there’d be a higher chance that Black people would want to take the vaccine.
The federal agency in charge of enforcing discrimination laws in the workplace said ‘yes,’ but there are some important exceptions and limitations.
Now that two COVID vaccines have been authorized by the FDA, questions arise. Today, a physician from Indiana University School of Medicine answers five reader questions.
A serious allergic reaction was reported in a health care worker in Alaska after she received the COVID-19 vaccine. Does this mean that people with allergies need to be concerned? An expert answers.
Experts from across The Conversation assess the work that’s helped us reach vaccine roll-out, how this could play out, and the risk of vaccine hesitancy.
Top contributors
-
Associate professor, UNSW Sydney
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Associate Professor, School of Social Sciences, The University of Western Australia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor, Epidemiology, Deakin University
-
Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Assistant Professor of Political Science, Oklahoma State University
-
Instructor of Human Immunology, Emory University
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Chair in Epidemiology, Deakin University
